Bristol-Myers Squibb and Concerto HealthAI have announced plans to apply artificial intelligence (AI) and real-world data to a diverse range of cancers in a multi-year strategic agreement.
The collaboration will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials, enable robust protocol design and generate insights for precision treatment and improved patient outcomes.
The partnership will give the American pharma giant access to Concerto’s eurekaHealth AI insights platform, in order to accelerate insights through novel health economic outcomes and clinical development synthetic control arm studies.
The platform will give Bristol-Myers Squibb access to over a decade of real-world patient data from geographically diverse community oncology practices.
“With the increasing importance of real-world data and real-world evidence, healthcare providers and regulators need to have confidence in the credibility and accuracy of the data sources and methods of evidence generation,” said Jeff Elton, and chief executive of Concerto HealthAI.
“Our agreement with Bristol-Myers Squibb is a recognition that we have reached a pivot-point for RWE – it is not just a tool for generating insights into the current standard of care, but a field in its own right that can lead to optimisation of current treatments and new therapeutic innovations.”
The agreement aims to advance the use of real-world evidence for regulatory purposes, validate clinical application of AI solutions and execute clinical studies to advance patient care.